Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
NNNN · Nasdaq · United States · In Vitro & In Vivo Diagnostic Substances
In shortAnbio Biotechnology is profitable.
Financial health
Solid
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 66.7% | 100/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 74.1% | 100/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 27.0% | 100/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | – | n/a |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 344.31× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | – | n/a |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | – | n/a |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | – | n/a |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 370.84 | 100/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -77.9% | 0/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | -1.05× | 0/100 |
| Years with positive free cash flow (last 5) | 3 of 4 | 69/100 |
Weight in the score: 20%
| Profitable years (last 5) | 4 of 4 | 100/100 |
|---|---|---|
| Years of revenue decline (last 5) | 1 of 3 | 44/100 |
| Revenue growth volatility | 49.9% | 0/100 |
| Operating margin volatility | 19.0% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | -28.4% | 0/100 |
|---|---|---|
| EPS growth, 3-year average | -98.9% | 0/100 |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
The last 4 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Revenue | 24 | 6.7 | 8.2 | 8.6 |
| Cost of revenue | 11 | 3.4 | 2.3 | 1.1 |
| Gross profit | 13 | 3.4 | 5.9 | 7.5 |
| Research & development | 0.2 | 0.1 | 0.5 | 0.2 |
| Selling, general & admin | 2.2 | 1.3 | 3.4 | 1.6 |
| Operating income | 10 | 2 | 2 | 5.8 |
| Interest expense | 0 | – | – | – |
| Pre-tax income | 10 | 2.3 | 2.4 | 6.4 |
| Income tax | – | 0 | 0 | 0 |
| Net income | 10 | 2.3 | 2.4 | 6.4 |
| Diluted EPS | $100,112.00 | $0.11 | $0.06 | $0.15 |
| Diluted shares (millions) | – | 21 | 42 | 44 |
370.84 Safe zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
5/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Dec 31, 2025 · Data updated Apr 7, 2026